The IPOX® Update 7/11/2026
U.S.
DuPont Registry Confidentially Files for U.S. IPO That Could Raise Several Hundred Million Dollars
DuPont Registry Group, a marketplace connecting buyers, sellers and collectors of luxury vehicles, has confidentially filed for a U.S. IPO that could take place as soon as 2026 and raise several hundred million dollars. The company specializes in high-end brands including Ferrari, Lamborghini and Rolls-Royce. Morgan Stanley, Barclays, Jefferies and Royal Bank of Canada have reportedly been selected to work on the offering, although the number of shares and proposed price range have not yet been determined. (Source)
Accor Selects Banks for Potential U.S. IPO of Ennismore at Estimated €3.2 Billion Valuation
Accor is preparing a potential U.S. IPO of Ennismore Lifestyle Group, the hospitality company behind The Hoxton and other lifestyle hotel brands. Goldman Sachs is leading the offering, with BNP Paribas and JPMorgan also arranging the listing and Société Générale working on the transaction. The IPO could occur as soon as 2026, while Bloomberg Intelligence has estimated that Accor may seek a valuation of approximately €3.2 billion for Ennismore. (Source)
Syntiant Files for Nasdaq IPO to Expand Low-Power AI Semiconductor Business
Syntiant Corp., an Irvine-based semiconductor and AI software company, has filed for a U.S. IPO and plans to list on Nasdaq under the symbol SYTN. The company develops low-power processors for on-device machine learning applications in earbuds, wearables, vehicles and industrial systems, and expanded through its acquisition of Knowles’ consumer MEMS microphone business. Syntiant reported revenue of $64.5 million and a net loss of $20.9 million for the quarter ended March 2026, with Citigroup, BofA Securities, UBS and Needham serving as underwriters. (Source)
Scribe Therapeutics Files for Nasdaq IPO to Fund CRISPR Gene-Editing Trial
Scribe Therapeutics, a CRISPR gene-editing biotechnology company co-founded by Nobel laureate Jennifer Doudna, has filed for a Nasdaq IPO. Proceeds are expected to support a Phase I trial of its CRISPR-X treatment for high cholesterol, with initial results anticipated in the first half of 2027. The company held $49.7 million in cash as of March 31, 2026, and disclosed a going-concern provision, while Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities are acting as joint bookrunners. (Source)
Europe
Digi Spain Prices €330 Million IPO at €5.60 per Share, Securing €100 Million Commitment
Digi Spain Telecom has priced its IPO at €5.60 per share, implying a post-listing market capitalization of approximately €1.66 billion and a maximum offering size of around €330 million, including the over-allotment option. The transaction comprises 26.8 million new shares raising approximately €150 million for the company, a €137 million secondary offering and an option covering up to 7.7 million additional existing shares. Global Portfolio Investments has made a binding €100 million investment commitment, while admission to the Spanish stock exchanges remains subject to market conditions and approval from the CNMV. (Source 1) (Source 2)
Asia-Pacific
Rebellions Targets South Korean IPO in 2027, Followed by Potential U.S. ADR Listing
Rebellions, a South Korean developer of neural processing units for AI inference, plans to pursue an IPO in South Korea during the first half of 2027, potentially followed by a U.S. ADR listing. The company was valued at approximately $2.34 billion after raising $400 million in March 2026 from investors including the Korea National Growth Fund, Saudi Aramco’s Wa’ed Ventures, Samsung, SK Hynix and SK Telecom. JPMorgan is acting as IPO underwriter, with the company targeting the first or second quarter of 2027 depending on market conditions and volatility. (Source)
Disclaimer: News summaries may contain mistakes. The information does not constitute financial advice, endorsement or recommendation and should not be considered as such.
